Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Lyme Disease Overview 6 Therapeutics Development 7 Pipeline Products for Lyme Disease - Overview 7 Lyme Disease - Therapeutics under Development by Companies 8 Lyme Disease - Pipeline Products Glance 9 Late Stage Products 9 Clinical Stage Products 10 Early Stage Products 11 Lyme Disease - Products under Development by Companies 12 Lyme Disease - Companies Involved in Therapeutics Development 13 LondonPharma Ltd 13 NovoBiotic Pharmaceuticals, LLC 14 Valneva SE 15 Lyme Disease - Therapeutics Assessment 16 Assessment by Monotherapy Products 16 Assessment by Target 17 Assessment by Mechanism of Action 19 Assessment by Route of Administration 21 Assessment by Molecule Type 23 Drug Profiles 25 azithromycin - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 lyme disease vaccine 2 - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 Nu-3 - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 Small Molecule for Lyme Disease - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 Small Molecules for Lyme Disease - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 VLA-15 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 Lyme Disease - Dormant Projects 32 Lyme Disease - Product Development Milestones 33 Featured News & Press Releases 33 Mar 24, 2016: VALNEVA to present at the 16th World Vaccine Congress in Washington D.C. 33 Appendix 34 Methodology 34 Coverage 34 Secondary Research 34 Primary Research 34 Expert Panel Validation 34 Contact Us 34 Disclaimer 35

List of Tables Number of Products under Development for Lyme Disease, H2 2016 7 Number of Products under Development by Companies, H2 2016 8 Comparative Analysis by Late Stage Development, H2 2016 9 Comparative Analysis by Clinical Stage Development, H2 2016 10 Comparative Analysis by Early Stage Development, H2 2016 11 Products under Development by Companies, H2 2016 12 Lyme Disease - Pipeline by LondonPharma Ltd, H2 2016 13 Lyme Disease - Pipeline by NovoBiotic Pharmaceuticals, LLC, H2 2016 14 Lyme Disease - Pipeline by Valneva SE, H2 2016 15 Assessment by Monotherapy Products, H2 2016 16 Number of Products by Stage and Target, H2 2016 18 Number of Products by Stage and Mechanism of Action, H2 2016 20 Number of Products by Stage and Route of Administration, H2 2016 22 Number of Products by Stage and Molecule Type, H2 2016 24 Lyme Disease - Dormant Projects, H2 2016 32 List of Figures Number of Products under Development for Lyme Disease, H2 2016 7 Number of Products under Development by Companies, H2 2016 8 Comparative Analysis by Early Stage Products, H2 2016 11 Assessment by Monotherapy Products, H2 2016 16 Number of Products by Targets, H2 2016 17 Number of Products by Stage and Targets, H2 2016 17 Number of Products by Mechanism of Actions, H2 2016 19 Number of Products by Stage and Mechanism of Actions, H2 2016 19 Number of Products by Routes of Administration, H2 2016 21 Number of Products by Stage and Routes of Administration, H2 2016 21 Number of Products by Molecule Types, H2 2016 23 Number of Products by Stage and Molecule Types, H2 2016 23

LondonPharma Ltd NovoBiotic Pharmaceuticals, LLC Valneva SE